Syros Pharmaceuticals (NASDAQ:SYRS) Now Covered by Analysts at StockNews.com

StockNews.com started coverage on shares of Syros Pharmaceuticals (NASDAQ:SYRS) in a report released on Thursday. The brokerage issued a sell rating on the stock.

Other equities research analysts have also issued research reports about the company. Brookline Capital Management reissued a “hold” rating on shares of Syros Pharmaceuticals in a research note on Wednesday, November 13th. JMP Securities reiterated a “market perform” rating on shares of Syros Pharmaceuticals in a research report on Wednesday, November 13th. HC Wainwright restated a “neutral” rating and issued a $1.00 price target (down previously from $6.00) on shares of Syros Pharmaceuticals in a research report on Wednesday, November 13th. Piper Sandler reiterated an “overweight” rating and issued a $5.00 price objective (down from $13.00) on shares of Syros Pharmaceuticals in a research report on Tuesday, August 13th. Finally, TD Cowen restated a “hold” rating on shares of Syros Pharmaceuticals in a report on Wednesday, November 13th. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating and one has assigned a buy rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus target price of $3.33.

Syros Pharmaceuticals Stock Performance

Shares of SYRS opened at $0.29 on Thursday. The company has a debt-to-equity ratio of 1.97, a quick ratio of 2.25 and a current ratio of 2.25. The stock has a market capitalization of $7.87 million, a P/E ratio of -0.10 and a beta of 1.59. The company’s fifty day moving average is $1.85 and its two-hundred day moving average is $3.58. Syros Pharmaceuticals has a 1 year low of $0.18 and a 1 year high of $8.17.

Syros Pharmaceuticals (NASDAQ:SYRS) last announced its quarterly earnings data on Thursday, October 31st. The company reported ($0.68) EPS for the quarter, beating the consensus estimate of ($0.76) by $0.08. During the same quarter last year, the firm posted ($1.35) earnings per share. On average, sell-side analysts predict that Syros Pharmaceuticals will post -2.94 earnings per share for the current year.

Insider Transactions at Syros Pharmaceuticals

In other news, CEO Conley Chee bought 50,000 shares of the firm’s stock in a transaction that occurred on Tuesday, September 10th. The shares were purchased at an average price of $1.51 per share, for a total transaction of $75,500.00. Following the completion of the transaction, the chief executive officer now owns 72,504 shares in the company, valued at $109,481.04. The trade was a 222.18 % increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, CFO Jason Haas purchased 45,344 shares of the business’s stock in a transaction on Thursday, September 12th. The stock was acquired at an average price of $1.68 per share, with a total value of $76,177.92. Following the completion of the acquisition, the chief financial officer now directly owns 124,552 shares in the company, valued at $209,247.36. The trade was a 57.25 % increase in their position. The disclosure for this purchase can be found here. Insiders purchased a total of 130,707 shares of company stock valued at $206,491 over the last three months. 12.26% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of SYRS. Opaleye Management Inc. raised its holdings in Syros Pharmaceuticals by 119.1% in the 1st quarter. Opaleye Management Inc. now owns 787,545 shares of the company’s stock valued at $4,213,000 after acquiring an additional 428,175 shares during the last quarter. Kennedy Capital Management LLC acquired a new position in Syros Pharmaceuticals in the 1st quarter valued at $2,166,000. Vanguard Group Inc. raised its holdings in Syros Pharmaceuticals by 21.3% in the 1st quarter. Vanguard Group Inc. now owns 928,046 shares of the company’s stock valued at $4,965,000 after acquiring an additional 163,234 shares during the last quarter. Certuity LLC acquired a new position in Syros Pharmaceuticals in the 2nd quarter valued at $109,000. Finally, Acadian Asset Management LLC raised its holdings in Syros Pharmaceuticals by 101.5% in the 2nd quarter. Acadian Asset Management LLC now owns 34,578 shares of the company’s stock valued at $178,000 after acquiring an additional 17,416 shares during the last quarter. 91.47% of the stock is currently owned by institutional investors and hedge funds.

Syros Pharmaceuticals Company Profile

Syros Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development of treatment for hematologic malignancies. The company's lead product candidates are Tamibarotene, a selective retinoic acid receptor alpha agonist, which is in Phase III clinical trial for genomically defined subset of patients with myelodysplastic syndrome and Phase II clinical trial for patients with acute myeloid leukemia; SY-2101, a novel oral form of arsenic trioxide for treating patients with acute promyelocytic leukemia; and SY-5609, a cyclin-dependent kinase 7 inhibitor, which is in a Phase I clinical trial in patients with select advanced solid tumors.